Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals to Acquire Ion Channel Cell Line Provider Cytomyx

NEW YORK, March 14 (GenomeWeb News) - Serologicals will acquire Cytomyx, a wholly owned subsidiary of Cytomyx Holdings, Serologicals said today.

 

"Through this acquisition, our drug-discovery business will expand their service offerings to include GPCRs, kinases, and ion channels, the top three most-important target classes today," said Serologicals president and CEO, David Dodd in a statement.

 

Cytomyx has 23 ion channel cell lines commercially available and more in its pipeline, said Serologicals.

 

Serologicals expects to complete the acquisition in the first quarter of 2006 and for the acquisition to be "slightly accretive" in fiscal year 2006.

 

Financial details were not provided.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.